Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program

Breast

Volumn 15, Issue 1 SUPPL., 2006, Pages 30-40

  Aapro, M ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Antiaromatase agents; Bone loss; Breast cancer; Letrozole; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; ETIDRONIC ACID; EXEMESTANE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EARLY CANCER; ENDOMETRIUM CANCER; FLU LIKE SYNDROME; FRACTURE; HEALTH CARE COST; HIP FRACTURE; HUMAN; INCIDENCE; JAW DISEASE; LONG TERM CARE; MORBIDITY; MORTALITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SPINE FRACTURE; THROMBOEMBOLISM; WRIST FRACTURE;

EID: 33144467615     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.01.005     Document Type: Article

References (46)

1. J.R. Mackey A.A. Joy Skeletal health in postmenopausal survivors of early breast cancer Int J Cancer 114 2005 1010-1015
2. B.A. Mincey Osteoporosis in women with breast cancer Curr Oncol Rep 5 2003 53-57
3. National Institutes of Health. Osteoporosis and related bone disease. Bethesda, MD: National Resource Center, National Institutes of Health; 2003.
4. A.A. Ismail S.R. Pye W.C. Cockerill et al. Incidence of limb fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS) Osteoporos Int 13 2002 565-571
5. D. Felsenberg A.J. Silman M. Lunt et al. On Behalf of the EPOS Study Group. Incidence of vertebral fracture in Europe: Results from the European Prospective Osteoporosis Study (EPOS) J Bone Miner Res 17 2002 716-724
6. International Osteoporosis Foundation. Osteoporosis in the European community: A call to action-an audit of policy developments since 1998. Lyon: International Osteoporosis Foundation, 2003.
7. J. Lester D. Dodwell E. McCloskey R. Coleman The causes and treatment of bone loss associated with carcinoma of the breast Cancer Treat Rev 31 2005 115-142
8. J.A. Kanis E.V. McCloskey T. Powles A.H. Paterson S. Ashley T. Spector A high incidence of vertebral fracture in women with breast cancer Br J Cancer 79 1999 1179-1181
9. R.E. Coleman Metastatic bone disease: Clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165-176
10. R.E. Coleman Skeletal complications of malignancy Cancer 80 8 Suppl. 1997 1588-1594
11. M.S. Aapro Long-term implications of bone loss in breast cancer Breast 13 Suppl. 1 2004 S29-S37
12. A. Lipton R.L. Theriault G.N. Hortobagyi et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials Cancer 88 2000 1082-1090
13. J. Pfeilschifter I.J. Diel Osteoporosis due to cancer treatment: pathogenesis and management J Clin Oncol 18 2000 1570-1593
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
15. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351:1451-67.
16. B. Fisher J.P. Costantino D.L. Wickerham et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371-1388
17. Thürlimann B. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer, BIG 1-98: a prospective, randomized, double blind, phase III study. In: Proceedings of the Nineth International Conference on Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland, January 26-29, 2005. p.S3 [Abstract S4].
18. Howell A. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer-updated efficacy results based on a median follow-up of 5 years. Presented at the 24th Annual San Antonio Breast Cancer Symposium, December 2004 [Poster P1].
19. R.C. Coombes E. Hall L.J. Gibson et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081-1092
20. P.E. Goss J.N. Ingle S. Martino et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer N Engl J Med 349 2003 1793-1802
21. S.P. Boyce B. Mincey M. Duh et al. Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT) Proc Am Soc Clin Oncol 23 Suppl. 16 2005 44S [Abstract 665]
22. H.A. Harvey Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy Semin Oncol 31 Suppl. 12 2004 23-30
23. Delea T, McKiernan J, Brandman J, et al. Effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer. J Support Oncol, 2006, in press
24. M. Subar P.E. Goss J. Thomsen et al. Effects of steroidal and nonsteroidal aromatase inhibitors (antiaromatase agents) on markers of bone turnover and lipid metabolism J Clin Oncol 22 Suppl. 14 2004 [Abstract 8038]
25. A. Howell J. Cuzick M. Baum et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60-62
26. A. Howell Effect of anastrozole on bone mineral density: 2-year results of the Arimidex (anastrozole), tamoxifen, alone or in combination (ATAC) trial Br Cancer Res Treat 82 Suppl. 1 2003 129
27. P.E. Goss J.N. Ingle S. Martino et al. randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 2005 1262-1271
28. Kaufmann M, Rody A. Long-term risk of breast cancer recurrence: The need for extended adjuvant therapy. J Cancer Res Clin Oncol 2005 May 25 [Epub ahead of print].
29. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women completing ≥5 years (yrs) of adjuvant tamoxifen: Ncic ctg ma.17b. Presented at the 2004 San Antonio Breast Cancer Symposium, December 2004 [Abstract 404].
30. Coleman RE, Banks LM, Hall E, et al. Intergroup Exemestane Study: 1 year results of the bone sub-protocol. Presented at the 24th Annual San Antonio Breast Cancer Symposium, December 2004 [Abstract 401].
31. P.E. Lonning J. Geisler L.E. Krag et al. Changes in bone metabolism after 2 years treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: Follow-up (FU) results of a randomized placebo-controlled study J Clin Oncol 22 Suppl. 14 2005 11s [Abstract 531]
32. S.E. Jones J. Cantrell S. Vukelja S.J. Pippen et. al. The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer Proc Am Soc Clin Oncol 23 Suppl. 16 2005 31S [Abstract 610]
33. E.P. Winer C. Hudis H.J. Burstein et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004 J Clin Oncol 23 2005 619-629 [Epub 2004 Nov 15]
34. B.E. Hillner J.N. Ingle R.T. Chlebowski et. al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 2003 4042-4057 [Epub 2003 Sep 8. Erratum in: J Clin Oncol 2004;22:1351]
35. A. Lipton Y. Hei R. Coleman P. Major R. Cook Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome Proc Am Soc Clin Oncol 23 Suppl. 16 2005 11s [Abstract 532]
36. M. Gnant H. Hausmaninger H. Samonigg et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (±zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial Breast Cancer Res Treat 76 Suppl. 1 2002 S31 [Abstract 12]
37. Gnant M. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen-bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Presented at the 2004 San Antonio Breast Cancer Symposium, December 2004 [Abstract 5].
38. A. Brufsky G. Harker T. Beck et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the Z-FAST trial Proc Am Soc Clin Oncol 23 Suppl. 16 2005 12S [Abstract 533]
39. Brufsky A, Harker G, Beck T, et al. Z-FAST Study Group. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): Preliminary results of the Z-FAST trial. Presented at the 2004 San Antonio Breast Cancer Symposium, December 2004 [Abstract 1114].
40. N. Davidson P. Neven A. Llombart et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer Breast 14 Suppl. 1 2005 S44 [Abstract P105]
41. J.M. Stephens M.S. Aapro M.F. Botteman J.W. Hay J. Brandman A Markov model to evaluate the cost effectiveness of intravenous (IV) zoledronic acid vs IV generic pamidronate or oral ibandronate in the prevention of bone complications in breast cancer patients with bone metastases Proc Am Soc Clin Oncol 23 Suppl. 16 2005 S:44S [Abstract 664]
42. M.F. Botteman M.S. Aapro J.W. Hay J.M. Stephens J. Brandman Cost effectiveness of intravenous (IV) zoledronic acid vs other IV bisphosphonates for the prevention of bone complications in breast cancer patients with bone metastases: A Markov model from the UK perspective Proc Am Soc Clin Oncol 23 Suppl. 12 2005 58S [Abstract 721]
43. D. Göl A. Höer G. Schiffhorst J. Brandman B. Häussler Persistency with oral bisphosphonates in cancer patients Proc Am Soc Clin Oncol 23 Suppl. 16 2005 783S [Abstract 8221]
44. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 2005 May 31 [Epub ahead of print].
45. Alendronate (Fosamax) and risedronate (Actonel) revisited. Med Lett Drugs Ther 2005.47: 33-5.
46. J. Body M. Lichinitser S. Tjulandin M. Budde B. Bergström Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial Proc Am Soc Clin Oncol 23 Suppl. 12 2005 44S [Abstract 534]